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Research Article

Retigabine holds KV7 channels open and stabilizes the resting potential
Aaron Corbin-Leftwich, Sayeed M. Mossadeq, Junghoon Ha, Iwona Ruchala, Audrey Han Ngoc Le,
and Carlos A. Villalba-Galea

The Journal of General Physiology

Department of Physiology and Biophysics, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298

The anticonvulsant Retigabine is a KV7 channel agonist used to treat hyperexcitability disorders in humans. Retigabine shifts the voltage dependence for activation of the heteromeric KV7.2/KV7.3 channel to more negative
potentials, thus facilitating activation. Although the molecular mechanism underlying Retigabine’s action remains
unknown, previous studies have identified the pore region of KV7 channels as the drug’s target. This suggested that
the Retigabine-induced shift in voltage dependence likely derives from the stabilization of the pore domain in an
open (conducting) conformation. Testing this idea, we show that the heteromeric KV7.2/KV7.3 channel has at least
two open states, which we named O1 and O2, with O2 being more stable. The O1 state was reached after short membrane depolarizations, whereas O2 was reached after prolonged depolarization or during steady state at the typical
neuronal resting potentials. We also found that activation and deactivation seem to follow distinct pathways, suggesting that the KV7.2/KV7.3 channel activity displays hysteresis. As for the action of Retigabine, we discovered that
this agonist discriminates between open states, preferentially acting on the O2 state and further stabilizing it. Based
on these findings, we proposed a novel mechanism for the therapeutic effect of Retigabine whereby this drug reduces excitability by enhancing the resting potential open state stability of KV7.2/KV7.3 channels. To address this
hypothesis, we used a model for action potential (AP) in Xenopus laevis oocytes and found that the resting membrane potential became more negative as a function of Retigabine concentration, whereas the threshold potential
for AP firing remained unaltered.

INTRODUCTION

The heteromeric KV7.2/KV7.3 channel is the assembly of
KV7 channels most commonly found in the central nervous system (Jentsch, 2000; Cooper, 2012). The activity
of this heteromeric channel gives rise to the K+ current
that is suppressed by muscarinic signaling and is known
as the M current (Wang et al., 1998; Jentsch, 2000). M
currents are critical in controlling excitability in central
nervous system neurons (Brown and Adams, 1980; Wang
et al., 1998; Jentsch, 2000; Cooper, 2012; Linley et al.,
2012; Soh et al., 2014; Mastrangelo, 2015; Miceli et al.,
2015a). Indeed, mutations that detrimentally affect the
function of neuronal KV7 channels cause hyperexcitability syndromes such as benign familial neonatal seizures (Charlier et al., 1998; Singh et al., 1998), early
onset epileptic encephalopathy (Abidi et al., 2015), and
peripheral nerve hyperexcitability (Dedek et al., 2001;
Wuttke et al., 2007). Yet, the molecular basis for the role
of KV7 channels in the development of these disorders
remains unclear.
Epilepsy is a family of encephalopathies characterized
by abnormal synchronous and rhythmic neuronal activity in the brain that results in seizures. According to the

Centers for Disease Control and Prevention (CDC), 1%
of children aged 0–17 yr and 1.8% of adults aged 18 yr
or older have had a diagnosis of epilepsy or seizure disorder in 2013. This accounts for over five million people in the United States, with an estimate of 56% of
these identified cases being active epileptic patients
according to CDC estimates. Epileptic disorders are
life changing because they can cause learning disabilities and abnormal development in children. Epileptic
events can also be life threatening because tonic–clonic
(convulsive) seizures can cause out-of-control muscular
contractions resulting in injuries.
Epilepsy has a large genetic component (Cooper,
2012; Mastrangelo, 2015). However, some epileptic disorders, such as benign familial neonatal seizures, are
monogenic with causative mutations in the KCNQ2 or
KCNQ3 genes alone (Charlier et al., 1998; Singh et al.,
1998; Wang et al., 1998; Wuttke et al., 2007; Miceli et al.,
2011, 2015a,b; Cooper, 2012; Abidi et al., 2015). In these
cases, electrical hyperexcitability in neurons is caused
by ill-performing M currents (Brown and Passmore,
2009; Maljevic et al., 2010; Cooper, 2012). To compensate
for this deficiency, pharmacotherapeutic approaches
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have been focused on using drugs that boost the activity
of KV7 channels (Maljevic et al., 2010). Examples of KV7
agonists are Retigabine (Main et al., 2000; Rundfeldt
and Netzer, 2000b), Pyrithione Zinc (Xiong et al., 2007;
Linley et al., 2012), ICA-27243 (Wickenden et al., 2008),
and Diclofenac (Peretz et al., 2005). Retigabine is a first-inclass anticonvulsant that is currently used in the United
States to treat epileptic disorders in adults (Orhan et al.,
2012). This drug increases activity in Kv7 channels, except for KV7.1 (Wickenden et al., 2000, 2008; Peretz
et al., 2005; Wuttke et al., 2005; Gunthorpe et al., 2012).
This latter property makes Retigabine an attractive drug
for the treatment of neurological disorders, as no effect
on cardiac activity is expected.
Detailed understanding of both the physiological
behavior and the molecular basis for the activity of neuronal KV7 channels is needed for further refinement
of the available pharmacotherapy for KV7-related encephalopathies, as well as for the design of new ones. In
addressing this need, we have discovered that the deactivation kinetics of the heterotetrameric KV7.2/KV7.3
channel slows down as a function of activity. The changes
in the deactivation kinetics occurred in at least two stages,
revealing the existence of two open states, with the second open state being more stable than the initial one.
Further, we found that Retigabine’s action is state dependent, preferentially targeting channels in the more stable
open state. Furthermore, we found that channels that
are opened at the typical neuronal resting potential also
displayed two modes of activity with distinct deactivation
kinetics and sensitivity to Retigabine. These combined
observations led us to propose that, although Retigabine
can change the voltage dependence of activation for KV7
channels, the stabilization of the channels that are already opened at neuronal resting potential levels is the
clinically relevant effect of this anticonvulsant.

Sharp glass electrodes (resistance = 0.2–1 MΩ) were filled with a
solution containing (in mM) 1,000 KCl, 10 HEPES, and 10 EGTA,
pH 7.4 (KOH).
Electrophysiological data were filtered at 100 kHz, oversampled at 250 kHz to 2 MHz, and stored for off-line analysis at 5–25
kHz. For these recordings, a custom LabVIEW-based package was
used to control a multifunction data acquisition board (USB-6221
or USB-6251; National Instruments) for voltage command and
electrical signal acquisition. Data were analyzed using a custom
Java-based software and Origin2015 (OriginLab).
Oversampling
Oversampling is the process of sampling a signal at a frequency
much higher than the natural frequency of the system. Electrophysiological data are typically acquired at frequencies in the kilohertz range. For our study, the acquisition frequency (fa) for
currents or potential traces was 250 kHz to 2 MHz, after analogue
filtering at 100 kHz. The sampling frequency for traces was 5–25
kHz. To decrease high frequency noise, sampled points were calculated by averaging segments of fa/fs points from the acquired
data. The following example illustrates the process. When acquiring data at 1 MHz, we meant to obtain one acquired point every
1 µs; when sampling data at 10 kHz, we stored one data point
every 100 µs. To sample at 10 kHz, we averaged 100-point segments from the original trace that was acquired at 1 MHz.
“Loose” two-electrode voltage-clamp technique
APs were recorded using a modified two-electrode voltage-clamp
technique based on the implementation by Shapiro et al. (2012).
In brief, the command voltage was set to the resting membrane
potential of the oocytes, and the feedback gain was decreased to
prevent voltage-clamping. In addition, a 50-MΩ resistor in parallel
with a 10-MΩ in series with a diode was placed between the current-injecting microelectrode and the headstage. With the diode
anode placed on the headstage side, this arrangement allowed us
to inject current to depolarize the membrane and trigger APs, but
not to repolarize it.
Exponential fits and weighted average time constant
As described in previous studies (Lacroix et al., 2011; Labro et al.,
2012; Priest et al., 2013; Villalba-Galea, 2014), deactivating currents
were fitted to a two-exponential function defined as follows:
I DEACT (t ) = A1e

M AT E R I A L S A N D M E T H O D S
Electrophysiology
Defolliculated Xenopus laevis oocytes were injected with in vitro–
transcribed cRNA encoding for the human KV7.2 and KV7.3 channels in the vector pTLN. The KV7 constructs were provided by T.
Jentsch (Leibniz-Institut für Molekulaire Pharmakologie, Berlin,
Germany). These constructs were linearized with MluI and HpaI,
respectively (New England Biolabs, Inc.). The linearized DNA was
transcribed using SP6 RNA polymerase (mMessage mMachine;
Ambion). Potassium currents were recorded using the Xenopus
oocyte cut-open voltage-clamp technique using an amplifier (CA-1A;
Dagan Corporation). The external recording solution contained
(in mM) 12 KOH, 88 N-methly-d-glucamine, 100 methanesulfonic
acid, 10 HEPES, and 2 Ca(OH)2. The intracellular solution contained (in mM) 100 KOH, 100 methanesulfonic acid, 10 HEPES,
and 2 EGTA. Both solutions were titrated to pH 7.4 with methanesulfonic acid. Retigabine (Alomone Labs) was dissolved at 50 mM
in DMSO. The external solution used for control and washouts
was added with 0.002–0.02% (vol/vol) of DMSO to account for
the potential effect of the solvent on the activity of the channels.
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−t
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,

where A1 and A2 are the current amplitude associated with each
component and 1 and 2 are the corresponding time constants.
The deactivation time constant (DEACT) was calculated as
τ DEACT =

A1 τ1 + A2 τ2
.
A1 + A2

Fittings were done using Origin2015.
ITAIL–V plots fit to Boltzmann equations
To quantify the apparent voltage dependence for activation, ITAIL–V
plots were fitted to a two-Boltzmann equation defined as
I TAIL (V ) =

A1
− z1(V −V1 )
kT
1+e

+

A2
− z 2 (V −V2 )
kT
1+e

,

where A1 and A2 are the amplitude associated with each of the
components, V1 and V2 are the half-activation potential for each
component, z1 and z2 are the corresponding associated sensing
charges, k is the Boltzmann constant, and T is absolute temperature.

The weighted average half-maximum potential (weighted V1/2)
was calculated using the following equation:

weighted V1/2 =

A1V1 + A2V 2
.
A1 + A2

Fittings were done using Origin2015.

R E S U LT S
Stabilization of the open state of the KV7.2/KV7.3 channel

K+ currents were recorded from Xenopus oocytes co-injected with cRNA encoding for human KV7.2 and KV7.3
(Fig. 1 A). The activity of the expressed channels was
assessed by applying test pulses ranging from 120 to
+60 mV from a holding potential (HP) of 90 mV; K+
current amplitude readily increased when applying pulses
of 50 mV and above. After activation, K+ currents
were deactivated by applying a pulse to 105 mV (Fig. 1 A,
arrow). Using this protocol, we recorded K+ currents
that displayed the typical behavior voltage dependence
and time-lagged activation of heteromeric KV7.2/KV7.3
channels (Fig. 1). Focusing our attention on the closing

of the channels (Fig. 1 A, arrow), we noticed that the
deactivation rate of the K+ current decreased as the
magnitude of the test pulse increased. This feature was
made evident when normalizing the K+ current traces,
as we observed that the deactivation was slower when
occurring from a stronger activating stimulus (Fig. 1 B).
As previously reported in other studies (Lacroix et al.,
2011; Labro et al., 2012; Priest et al., 2013; Villalba-Galea,
2014), we quantified the deactivation time constant
(DEACT) of the K+ current by calculating the weighted
average time constant from the fitting of a two-exponential function to the deactivating current. The DEACT
versus test pulse potential (DEACT–VTEST) plot (Fig. 1 C)
showed an apparent linear dependence of 1.0 ± 0.2 ms
(n = 8) in the deactivation time constant per unit of
millivolt imposed during the activation, indicating that
the stability of the activated channel increases as a function of the channel activation.
In terms of stochastic discrete-state modeling of channel
activity (Colquhoun and Hawkes, 1977), we discerned
more than one DEACT, which points to the existence of
more than one open state. Also, the sigmoidal time course
of the K+ current activation indicates that this process

K+ deactivation rate decreases as a function of activation. (A) K+ currents recorded from Xenopus oocytes coexpressing human
KV7.2 and KV7.3 channels using the cut-open voltage-clamp technique. Test pulses ranging from 120 mV to +60 mV were applied from
an HP of 90 mV. Deactivation of the current was driven at 105 mV (arrow). (B) Normalized deactivating currents from activating
pulses from 30 to +60 mV. Deactivation slowed down after higher activating potentials. (C) Deactivation time constant (DEACT) versus
test pulse potential (DEACT–VPULSE) plot. Error bars represent standard deviation. (D) Kinetics scheme describing alternative pathways
for the deactivation of the heteromeric KV7.2/KV7.3 channel. Voltage-dependent transitions are noted with V.
Figure 1.
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involves transitions through multiple closed states preceding channel opening. For this study, we assumed,
therefore, that the activity of the heteromeric KV7.2/
KV7.3 can be described by a sequential model consisting
of a series of closed states leading to two open states, O1
and O2 (Fig. 1 D). In this case, deactivation for the open
state O2 will be slower, as this process will involve one
additional transition.
Effect of Retigabine on the deactivation of KV7.2/KV7.3

As before, we recorded K+ currents from oocytes co-injected with KV7.2 and KV7.3 from an HP of 90 mV. We
applied 1.2-s pulses from 100 to +60 mV followed by a
pulse to 105 mV to activate and deactivate the channels, respectively (Fig. 2 A). To assess the effect of Retigabine on the activation of KV7.2/KV7.3 channels, we
plotted the normalized amplitude of the deactivating
current (ITAIL) as a function of the activating potential
(VPULSE). The normalized ITAIL–VPULSE plots showed a
modest shift toward negative potential in the voltage dependence of channel activation as a function of the concentration of Retigabine (Fig. 2 B). In spite of this shift,
Retigabine seems not to greatly affect activation kinetics
(Fig. 2 A). In contrast, we observed that deactivation of
the K+ current was unambiguously slower in the presence

of the drug (Fig. 2 A, arrows), indicating that Retigabine was preferentially acting on open channels. Because KV7.2/KV7.3 possess at least two open states, we
proceeded to investigate whether Retigabine was able
to discriminate between them.
Retigabine preferentially binds to the open state O2

The activation of the KV7.2/KV7.3 channels can be increased by applying pulses of higher voltages, longer
duration, or both. Thus, to further explore how deactivation is affected by Retigabine, we studied how DEACT
changes as a function of the duration of the depolarization (DEACT–tPULSE plot). To do so, we recorded the deactivation of K+ current after activation by 40-mV pulses
of variable duration (Fig. 3 A) and analyzed how DEACT
changed as a function of the duration of the activating
pulse (tPULSE). We observed that deactivation became
slower as the activating pulse duration increased (Fig. 3 C,
black squares). We also noticed that DEACT did not
change for activating pulses shorter than 100 ms (Fig. 3 D,
black squares), indicating that the stability of the conducting channel increased as a function of activation
by depolarization lasting >100 ms. In terms of our initial
model (Fig. 1 D), these observations indicated that

Figure 2. Effect of Retigabine on the activity of the heteromeric KV7.2/KV7.3 channel. (A) K+ currents recorded in the absence or
presence of 1–5-µM Retigabine using the same protocol shown in Fig. 1. (B) Average normalized K+ current amplitude measured at the
beginning of the deactivating currents (ITAIL; arrows in A). Normalized ITAIL versus test pulse potential (ITAIL–VPULSE) plots incrementally
shift toward negative potentials as the concentration of Retigabine (RTG) was increased. Individual ITAIL–VPULSE plots were fitted to a
double Boltzmann distribution, and the weighted average half-maximum potential (weighted V1/2) was plotted as a function of the concentration of Retigabine (inset). Although the weighted V1/2 values were not statistically different, this parameter changed to more negative potentials as a function of the concentration of Retigabine in all our recordings. Error bars represent standard deviation. n = 5–8.
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within the first 100 ms of activation, the channels mainly
populate state O1.
In the presence of 1-µM Retigabine (Fig. 3 B), deactivation became slower than in the absence of the drug
(Fig. 3 C). Remarkably, Retigabine had no significant
effect on the deactivation kinetics after activation pulses
shorter than 500 ms. Therefore, we concluded that Retigabine stabilizes those channels in state O2.
Retigabine stabilizes channels in the open state at the
resting potential

Thus far, we have shown that Retigabine only targets
channels that have been activated for a few hundreds
of milliseconds. However, the duration of a typical neuronal AP is in the order of a few milliseconds (Bean,
2007). So, we wondered how Retigabine can have any

therapeutic effect if this drug is mainly affecting the second open state of the KV7.2/KV7.3 channel, which is
reached after a prolonged, nonphysiological depolarization. In addressing this question, we observed that a
1.2-s pulse to 60 mV from an HP of 90 mV was able
to activate 2 ± 2% (n = 10) and 6 ± 2% (n = 10) of the
maximum KV7.2/KV7.3 conductance observed in our
recordings in the absence and presence of 10-µM Retigabine, respectively (Fig. 2 B). Because a membrane
potential of 60 mV is within the range of a typical neuronal resting potential (Bean, 2007), we hypothesized
that this fraction of channels, which are opened in
steady state at the resting potential, may be able to reach
the open state O2. If so, these channels could constitute
the therapeutically relevant target of Retigabine. To test
this idea, we compared the deactivation kinetics of K+
currents at 90 mV from a pulse-activated open state

Deactivation time constant increase as a function of the duration of the activating pulse. (A and B) K+ currents were activated
by 40-mV pulses with a duration varying from 10 to 4,175 ms in the absence (A) and presence (B) of 1-µM Retigabine. The duration
of the pulse increased 1.3-fold for each trace. After activation, the K+ current was deactivated at 90 mV. (C) DEACT–tPULSE plot shows
that DEACT increased as the activating pulse was longer (black squares). In the presence of Retigabine, DEACT increased further. (D) The
same plot as in C, but the tPULSE is displayed in a logarithmic scale to highlight the DEACT–tPULSE relationship for shorter activating pulses
and showing that DEACT was unaltered by Retigabine for pulses shorter than 500 ms. Error bars represent standard deviation. Control,
n = 7; Retigabine, n = 6.
Figure 3.
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and from a resting potential open state. To assess the
first condition, we activated channels by applying a
100-ms pulse to 40 mV for an HP of 90 mV. To assess
the second condition, we held the membrane potential at 50 mV. When driving deactivation at 90 mV,
we observed that the pulse-activated K+ current deactivated faster (Fig. 4 A, black trace) than the resting potential–activated K+ current (Fig. 4 B, black trace).
These observations revealed that the open state reached
by the channels at steady-state resting potential was
more stable than the open state reached after a 100-ms
activating pulse. In light of these results, we then wondered whether this resting potential open state could
be further stabilized by Retigabine. To test this, we used
the same recording protocol, but in the presence of
1-µM Retigabine. Deactivation from the pulse-activated
current was not significantly affected by the drug (Fig. 4 A,
red trace). In contrast, the deactivation rate from the
resting potential–activated current was unambiguously decreased by the drug (Fig. 4 B, red trace). This
observation indicated that the stable open state reached
at the typical neuronal resting potential was sensitive
to Retigabine.

To further investigate the differential effect of Retigabine on channel closing, we carried out a detailed analysis of the effect of the membrane potential on the
deactivation of the channel. For this, we recorded K+
currents deactivating at different potentials from either
the pulse-activated open state (Fig. 4 C) or the resting
potential open state (Fig. 4, D–F). In all cases, we observed that DEACT decreased as the deactivating potential was more negative (Fig. 4, C–F). Deactivation of the
K+ currents activated at the resting potential was 10fold slower than deactivation of the pulse-activated currents at all deactivating potentials. As before, in the
presence of Retigabine, deactivation of the pulse-activated currents showed no significant changes in DEACT
with respect to control (Fig. 4 C). In contrast, Retigabine
significantly increased DEACT for resting potential–activated currents depending on the deactivating potentials
and the HP imposed to activate the currents. Particularly, when channels were activated at an HP of 60 mV,
DEACT increased only when deactivation was driven at
potentials above 90 mV (Fig. 4 D). Holding the membrane potential at 50 mV (Fig. 4 E) enhanced the
effect of Retigabine, making DEACT significantly larger

Figure 4. Deactivation from the depolarized and resting potential open states. (A) Deactivation at 90 mV of the K+ current elicited by
a 100-ms depolarization to 40 mV in the absence (black trace) and presence of 1-µM Retigabine (red trace). (B) Deactivation at 90 mV
of the K+ current elicited by holding the membrane potential at 50 mV also in the absence (black trace) and presence of 1-µM Retigabine (red trace). (C–-F) Deactivation time constant (DEACT) versus deactivating potential (DEACT–VDEACT) plot of channels activated by a
100-ms depolarization to 40 mV (C) or by holding the membrane potential at 60 mV, 50 mV, and 40 mV (D, E, and F, respectively)
in the absence (black squares) and presence of 1-µM Retigabine (RTG; red circles). Error bars represent standard deviation. t test; n =
5–8. *, P < 0.05, t test.
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when deactivating potentials were above 100 mV. Activation at 40 mV (Fig. 4 F) resulted in a further enhancement of the drug’s effect, increasing DEACT at all
the deactivating potentials that we tested (Fig. 4 F).
These observations suggested that stabilization of the
open pore by Retigabine increases the energy barrier
for deactivation, which has to be overcome by the electrical work the electrical field does on the voltage-sensing domains (VSDs). Therefore, making the membrane
potential more negative provides more energy for the
VSD to overcome the Retigabine-induced stabilization
of the open pore.
Retigabine modulates AP triggering in Xenopus oocytes

Thus far, we have shown that, on one hand, Retigabine
has no significant effect on deactivation of the heteromeric KV7.2/KV7.3 channels that are activated by short
depolarizing pulses. In contrast, Retigabine stabilizes
channels that are already opened at the resting potential. These observations are consonant with the notion
that Retigabine induces hyperpolarization of the plasma
membrane (Main et al., 2000; Tatulian et al., 2001;
Wainger et al., 2014). On the other hand, the activation
of KV7.2/KV7.3 seems to be too slow to significantly contribute to the increase of the K+ conductance during a
typical neuronal AP. Therefore, we hypothesized that
Retigabine would have little or no effect on AP repolarization. To further test this view, we decided to evaluate
the effect of this anticonvulsant on the generation of
AP in a system with a defined background of channel
expression. To do so, we co-injected Xenopus oocytes with
cRNAs encoding for the sodium-selective, voltage-gated
channel NaV1.4 ( and  subunits) and the KV channels ShakerIR, KV7.2, and KV7.3. From such oocytes, we
were able to evoke AP-like electrical activity using a
modified (“loose”) two-electrode voltage-clamp technique (see Materials and methods for details; Shapiro
et al., 2012). Using this approach, we were able to depolarize the membrane to evoke APs while being able
to poorly voltage-clamp the oocytes (Fig. 5 A). From a
resting potential (VREST) near 60 mV, a brief (0.25–
0.75 ms) depolarization of the membrane was induced
by current injection. If the depolarization failed to
evoke an AP, the membrane potential retuned to its
resting value within the next 100 ms (Fig. 5 A, gray
trace). However, if an AP was successfully triggered,
repolarization was achieved within a few milliseconds
after the peak of the AP (Fig. 5 A, black trace). Under
our experimental conditions, the minimum amplitude
of the current required to evoke an AP (ITHR) ranged
between 1 and 5 A. In the presence of 1-µM Retigabine (Fig. 5 A, red trace), VREST tended to become more
negative (Fig. 5 B), requiring an increase of 30% in the
magnitude of ITHR to reach the threshold potential for
evoking an AP (VTHR; Fig. 5 C). For 10-µM Retigabine,
the resting membrane potential became more negative


with respect to control (Fig. 5 B), requiring a further
increase in ITHR, 86%, to reach VTHR (Fig. 5 C). In spite
of the unambiguous effect of 10-µM Retigabine on
VREST, Retigabine seemed not to affect VTHR, as this parameter remained fairly constant in the presence of the
drug (Fig. 5 B). Because VTHR is the potential at which
the inwardly rectifying Na+ cancels the outwardly rectifying K+ current, we reasoned that the slow response
of the heteromeric KV7.2/KV7.3 channel to changes in
membrane potential results in a negligible increase in
the contribution of these channels to the K+ conductance during a single AP. Therefore, the VTHR was mainly
determined by the activation of NaV1.4 and ShakerIR,
both of which are not sensitive to Retigabine.
To further evaluate the effect of Retigabine on our
oocyte AP model, we generated phase plots from rec
ords of the membrane potential (VM) during an AP.
Phase plots are built by plotting the first derivative of VM
with respect to time (dVM/dt) as a function of the VM
itself (Bean, 2007). Starting at VREST (Fig. 5 D, star), injecting current depolarized the membrane. This was
seen as a transient positive deflection in the phase plot
(Fig. 5 D, stimulation [purple arrow]). At the end of the
current injection, VM was more positive, but dVM/dt
went back to zero. At this point, if VTHR was reached
during current injection (Fig. 5, A and D, solid yellow
arrow), an AP was evoked. As NaV channels were activated, depolarization appeared as a rapid increase in
dVM/dt, driving the VM to more positive voltages (Fig. 5 D,
AP depolarization [green arrow]). Then, the combination of inactivation of NaV channels and activation of
KV channels resulted in the decrease of dVM/dt to zero,
at which the peak voltage of the AP is reached (Fig. 5 D,
open blue arrow). After the peak, dVM/dt became negative as the repolarization phase of the AP started. This
late phase was driven by the activity of KV channels. Remarkably, we observed that the late phase of the repolarization was unaltered by Retigabine (Fig. 5 D, open
yellow arrow). These observations were consistent with
the idea that KV7 channel activation was too slow to be
increased within the time of a single AP. Furthermore,
Retigabine caused the peak of the AP to be more positive. We interpreted this to be the result of the recovery
of NaV channels from steady-state inactivation as a consequence of the VREST hyperpolarization (Fig. 5 C). Based
on these results, we concluded that the effect of Retigabine on excitability was restricted to the modulation of
the resting potential open state of the heteromeric
KV7.2/KV7.3.
DISCUSSION

In agreement with previous studies, our data show that
Retigabine enhanced the activity of KV7.2/KV7.3 channels. Previous publications have reported that Retigabine
boosts channel activity by shifting the voltage dependence
Corbin-Leftwich et al.
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The resting potential, but not the threshold potential for triggering AP, was affected by Retigabine. (A) APs were recorded
from Xenopus oocytes coexpressing both the  and  subunits of NaV1.4, ShakerIR, KV7.2, and KV7.3. The APs were recorded using the
loose two-electrode voltage-clamp technique (see Materials and methods for details) in the absence (black trace) or presence of 1-µM
(red trace) or 10-µM (green trace) Retigabine. The gray trace shows the response of VM when a subthreshold was applied. The arrow
indicates the moment at which AP threshold (VTHR) is reached. (B) Effect of Retigabine (RTG) on the resting membrane potential
(VREST) and AP threshold (VTHR). (C) Minimum current injection needed to evoke an AP (ITHR). The values of ITHR were normalized by
ITHR in the absence of Retigabine (n = 4). (D) Example of a phase plot calculated from the APs shown on A. VREST was strongly affected
by Retigabine (blue star), whereas VTHR remained fairly unaltered. Although the depolarization phase was affected by Retigabine (blue
arrow), the late phase of repolarization (yellow arrow) remained unaltered. Arrows indicate the progress of the AP in time during the
stimulation phase (purple arrow), depolarization phase (green arrow), and repolarization phase (orange arrow). The open blue arrow
points at the times when APs reached their maximum voltage. The open yellow arrow points at the late repolarization phase. Error bars
represent standard deviation. t test; n = 5. *, P < 0.002 with respect to control; **, P < 0.07 with respect to 1-µM Retigabine; ***, P < 0.0025
with respect to control; #, P < 0.072 with respect to control.
Figure 5.

for K+ current activation toward more negative values
(Rundfeldt and Netzer, 2000a,b; Wickenden et al., 2000;
Schenzer et al., 2005; Wuttke et al., 2005; Gunthorpe
et al., 2012; Orhan et al., 2012; Kim et al., 2015). Although
our observations are consonant with these previous studies (Fig. 2 B), we argue that the effect of Retigabine on
the deactivation kinetics have a deeper impact on excitability than the change in voltage dependence that facilitates channel activation. On this topic, we would like
to point out that the relative slow activation kinetics of
KV7.2/KV7.3 channels with respect to the lifetime of an
AP strongly suggests that the number of activated KV7
channels remains constant during this type of electrical
event. Hence, slowing down the deactivation of channels
that are already opened at the resting potential seems
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to have a higher impact on the activity of KV7.2/KV7.3
channels during neuronal activity.
We observed that, along with a slight shift in the voltage dependence for activation, Retigabine mainly stabilized KV7.2/KV7.3 channels that were already opened.
Further, we also observed that these channels deactivate
in two modalities, revealing the existence of at least two
types of open states, with deactivation from the second
(O2) open state being slower (Figs. 3 and 4). Furthermore, we also discovered that Retigabine discriminated
between these two types of open states, decreasing the
deactivation rate from the open state O2 (Fig. 1 D). This
latter finding confirmed the existence of at least two
open states, as they were distinguished not only by their
deactivation kinetics, but also by their distinct sensitivities

to Retigabine. Combined, these observations cast doubts
on the notion that the clinically relevant effect of Retigabine is to facilitate channel activation. Instead, our
findings indicate that Retigabine stabilizes those channels that have been already activated.
Inquiring about the mechanism of KV7.2/KV7.3 channel activity, we wondered whether the two open states or
modes were the consequence of the channels being
formed by two different types of subunits, KV7.2 and
KV7.3. This idea requires that the stabilization of the
conductance is caused by differential contributions of
both subunit types to the conductive states of the channels. If so, this would imply that Retigabine is acting
only on one type of subunit, as only the deactivation of
the more stable open state is affected by the drug. However, both KV7.2 and KV7.3 are sensitive to Retigabine
(Main et al., 2000; Rundfeldt and Netzer, 2000b; Wuttke
et al., 2005, 2008; Kim et al., 2015). Thus, this later possibility is likely not probable. Therefore, we argue that
the two different open states are not caused by the heteromeric nature of the channel.
The lack of effect of Retigabine on the stabilization of
O1 indicates that these modes likely represent distinct
sets of conformations of the activated channel. Thus,
the emerging question is, which of the available KV7
channel models corresponds to the state O2? Addressing this question highlights that a detailed understanding of the atomic interactions underlying the effect of
anticonvulsants is needed to expedite the development
of new drugs. A few residues in the intracellular side of
the pore have been identified as critical for the inter
action of KV7 channels and Retigabine. Among them, a
Tryptophan on the channel’s fifth transmembrane (S5)
segments, namely W236 in KV7.2 (Schenzer et al., 2005;
Wuttke et al., 2005) and the corresponding W265 in
KV7.3 (Schenzer et al., 2005; Kim et al., 2015), is a key
player for the atomic interaction underlying the action
of Retigabine, whereby removing a single hydrogen
bond impairs drug action (Kim et al., 2015). Thus, the
structural differences associated with the open states O1
and O2 may depend on subtle rearrangements within
the pore domain.
One outstanding question is why the changes in voltage dependence of activity that we observed were much
lower than reported by other laboratories. We assessed
voltage dependence of the KV7.2/KV7.3 channel using a
pulse protocol like the one shown in Fig. 2 A. During
the initial stages of this project, we observed that Retigabine changed the voltage dependence for current
activation over 20 mV. However, we also noticed that
increasing the duration of the period of time between
each trace (intertrace intervals) from 1–2 s to 10–25 s
decreased the shift in voltage dependence. So, we modified our protocols and, regretfully, did not systematically
follow up on this matter at that time; we are currently
addressing this issue, as further experiments are needed.


Nevertheless, as shown in Fig. 4, DEACT at 90 mV can
reach >2 s. This implies that, assuming a single exponential process for closing, it will take at least 10 s to
close 99% of the channels. Based on these observations,
we concluded that short intertrace intervals may lead to
overestimating the shift in the voltage dependence for
activation because using short intertrace intervals does
not allow channels to fully deactivate.
One intriguing observation made in this study is that
the VTHR for triggering AP remained unaltered by the
drug. Although we did not directly address this issue, we
argue that the increased robustness of the K+ conductance caused by the stabilization of the opened KV7 channels by Retigabine could be compensated for by the
increase of the number of available Na+ channels rescued
from steady-state inactivation. Favoring this idea, we
found that the amplitude of the AP tended to increase as
VREST hyperpolarized (Fig. 5 A). Furthermore, we noticed
that the delay between stimulation and the peak of APs
shortened in the presence of 10-µM Retigabine, which is
also consistent with an increase in the number of NaV
channels driving depolarization (Fig. 5 A). In addition to
these indirect effects of Retigabine on the availability of
NaV channels, the closing of KV7.2/KV7.3 channels by hyperpolarization may have relieved the channels from the
action of Retigabine, as this drug only acts on channels
dwelling in the open state O2. Therefore, in an apparent
paradox, we propose that Retigabine action constitutes a
negative feedback loop. As stabilization of the open KV7
channels drives hyperpolarization of the plasma membrane, channels tend to close. In turn, channels in closed
states are less sensitive to Retigabine. Therefore, the overall
effect of the drug decreases.
Another outstanding question is why the effect of Retigabine diminished when deactivation was driven at
more negative potentials (Fig. 4). On one hand, here,
we have shown that Retigabine stabilizes those channels
that are already opened either by a prolonged depolarizing pulse or at steady state at the typical neuronal resting potential. On the other hand, other laboratories
have shown that the putative binding site for Retigabine
is located at the intracellular side of the central pore
domain of KV7 channels (Schenzer et al., 2005; Wuttke
et al., 2005; Lange et al., 2009; Kim et al., 2015). Thus,
we concluded that our results could be readily explained by a kinetic scheme like the one described in
Fig. 1 D. However, we argue that this scheme may not be
consonant with the current understanding of the mechanism of activity of KV channels. The canonical KV channel is a tetrameric protein with a central pore domain
controlled by four VSDs surrounding it (Long et al., 2005,
2007). Activation of KV channels occurs as membrane
depolarization drives conformational changes in the
VSDs (Bezanilla, 2008) that lead to the opening of the
central pore by a coupling mechanism that is not fully
understood (Vargas et al., 2012). Likewise, deactivation
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of KV channels is caused by the repolarization of the
plasma membrane that drives VSDs toward their initial
resting conformation, which, in turn, closes the central
pore. As already mentioned, one interpretation for these
results is that, at more negative potential, the increased
driving force for the movement of the VSD provides
enough energy to overcome the effect of Retigabine.
Another aspect to be considered is that the sequence
of events inherent to the closing of channels is not exactly the reverse sequence of events observed during
the opening; changes in the conductive status is always
initiated by electrically driven changes in the VSD. In
this view, activation and deactivation follow distinct
pathways that may display distinct voltage sensitivities.
Indeed, a commonly overlooked feature of KV channels
and other VSD proteins is that their activity displays hysteresis (Bezanilla et al., 1982; Shirokov et al., 1992; Olcese
et al., 1997; Pennefather et al., 1998; Piper et al., 2003;
Kuzmenkin et al., 2004; Männikkö et al., 2005; VillalbaGalea et al., 2008; Akemann et al., 2009; Xiao et al., 2010;
Lacroix et al., 2011; Benndorf et al., 2012; Labro et al.,
2012; Priest et al., 2013; Villalba-Galea, 2014; Li et al.,
2015). Hysteresis is a property of many physical and
chemical systems whereby their response to a stimulus
depends on whether the magnitude of the stimulus is
increasing or decreasing. In KV channels, hysteresis is
manifested as a shift in the voltage dependence of their
activity, a decrease in the deactivation rate, or both (Olcese
et al., 1997; Pennefather et al., 1998; Piper et al., 2003;
Lacroix et al., 2011; Labro et al., 2012; Priest et al., 2013).
In the case of ShakerIR and KV1.2, the relationship between DEACT and duration of the activation pulse (DEACT–-tPULSE plot) increases in three stages: the first one in
which DEACT is small and remains constant, a second
stage in which DEACT increases, and a third stage in
which DEACT reaches a plateau (Labro et al., 2012). The
first stage is associated with stabilization of the open
pore, and the last stage is the result of VSD relaxation.
This latter process is a hysteretic mechanism that is intrinsic of the VSD (Villalba-Galea et al., 2008, 2009,
2013; Akemann et al., 2009; Lacroix et al., 2011; VillalbaGalea, 2012, 2014). Here, we show that the DEACT–tPULSE
plot for KV7.2/KV7.3 also displays three stages, with the
third one, however, not reaching a plateau within the
time frame used in these studies. This observation suggests that the deactivation for state O2 follows a distinct
voltage-dependent pathway, implying that the activity of
KV7.2/KV7.3 is hysteretic. In this view, stabilizing the
pore domain in an open conformation can cause a shift
in voltage dependence, as channel closing will require
more energy.
According to the sequential model in Fig. 1 D, depolarization drives the VSDs from their deactivated conformations to the activated ones. In doing so, the energy
gained by this electrical work drives the opening of the
pore to the first open state (O1). Eventually, the second
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open state (O2) is reached from O1. In the presence of
Retigabine, the stability of O2 is enhanced. According
to the scheme in Fig. 1 D, deactivation only occurs from
O1, which implies that channels need to be relieved from
the action of the drug before closing. Although this is a
possible scenario, in terms of the current understanding of structure-function of channels, there is no reason
to believe that the VSD will not deactivate from state O2.
Based on this idea, we argue that the initial scheme depicted in Fig. 1 D seems to be insufficient to describe
our findings. To address this issue, we have modified
our original kinetic scheme to explicitly define the VSDs
and pore as intrinsically independent modules that are
coupled (Fig. 6). For simplicity, we represented the activation of four VSDs to occur in a single step instead of
the explicit 16 states emerging from all the possible
combinations of activated and deactivated VSDs and
pore domain. Also, another simplification implemented
is that we did not make any explicit distinction between
KV7.2 and KV7.3 subunits. The purpose of this new scheme
(Fig. 6) is to illustrate a basic framework that allows us
to describe our findings in terms of what we know on
the dynamics of VSD proteins. According to the new
scheme, hyperpolarization of the membrane drives the
four VSDs into their deactivated conformation (VSDD),
which in turn keeps the pore closed (PC0; Fig. 6, state
VSDD/PC0). As the membrane potential becomes more
positive (e.g., at the membrane resting potential), VSD
sojourns between the VSDD and the activated (VSDA)
state, allowing the pore to also sojourn between the
nonconductive (PC1) and the conductive (PO1) states
(Fig. 6). If the membrane is immediately hyperpolarized, VSD deactivates, driving the pore domain back to
state PC0. In contrast, holding the membrane at the resting potential will allow the pore to eventually change
conformation into a second set of open (PO2) and closed
(PC2) states. From these new states, deactivation is slower,
as the pore has stabilized. In addition, the channels become Retigabine sensitive, so that in the presence of
this drug, the pore is further stabilized and deactivation
becomes slower.
Open pore stabilization provides a straightforward
mechanism for hysteresis in KV channels. However, the
charge movement of an isolated VSD can also show
hysteresis through an intrinsic process known as VSD
relaxation (Villalba-Galea et al., 2008, 2009). After relaxation, the voltage dependence for charge movement
(sensing/gating currents) can shift to more negative
potentials as well as to become slower. This implies that
hysteresis in KV7 channels could also originate from
VSD relaxation (Lacroix et al., 2011; Labro et al., 2012).
Our observations, alas, do not allow us to evaluate this
possibility, as we have not been able to record gating
currents from KV7.2/KV7.3.
In spite of the findings reported here, the overall
impact that hysteresis can have on electrical signaling

Figure 6. Proposed kinetic scheme for the activity of KV7.2/KV7.3 and the effect of Retigabine.
The scheme contains five global states, which are
different with respect to each other depending
on the activation status of the VSD and the pore
domain (P). In the scheme, VSD represents the
four voltage sensors of the channel. At negative
potentials, the VSDs are in the deactivated state
(VSDD) and the pore is, therefore, closed (PC0).
Upon depolarization, the VSDs are activated
(VSDA), allowing the pore to sojourn between a
conductive and a nonconductive state (PO1 and
PC1, respectively). Holding the membrane depolarized potentials keeps the VSDs in the VSDA
state while allowing a second transition in the
pore. As a result, the pore sojourns between a
second pair of conductive and nonconductive
states (PO2 and PC2, respectively) and the channel
becomes Retigabine sensitive. Deactivation from
these states is slower than from the pair PC1–PO1.
Retigabine further decreases the rate of deactivation from the pair PC2–PO2 while leaving deactivation unaffected from the other pair.

and its biological role remain elusive. Here, for the first
time, we provide an example of hysteresis in the activity
of a KV channel that directly affects the channel’s pharmacology under physiological conditions. In line with
recent findings on the action of Retigabine on the isolated pore of KV7 channels (Syeda et al., 2015), our observations clearly show that the stabilized open state of
the KV7.2/KV7.3 channel is the target for the action
of the anticonvulsant Retigabine. These findings have
several implications. First, using the effect on the activation of the KV7 channels is an important but not sufficient parameter when evaluating new drugs targeting
the activity of these channels. Second, the observation of
a hysteretic behavior in the activity of KV7 channels
implies the existence of two or more distinct sets of
open states. These sets of states are likely associated with
also structurally distinct sets of conformations. Our results showed that Retigabine can differentially affect
the stability of these states, confirming that the channel
adopts a different set of conformations that can be
pharmacologically discriminated. It remains to be established, however, whether the stabilization of the second
open state (O2) is driven by conformational changes in
the pore, VSD relaxation, or both. For this, future studies will need to directly study the dynamics of the VSD
and determine whether the VSD of KV7 channels relaxes. On this issue, no study showing gating currents
from these channels has been reported to our knowledge. Recording gating currents from both KV7.2 and
KV7.3 has proven technically challenging, as we also
failed to record gating currents during the present
study. At this point, we can conclude that, although it
seems that Retigabine is acting on the pore domain, we
cannot rule out the possibility that VSD relaxation is involved in the stabilization of the open state.


On a final note, knowing that the activation of KV7.2/
KV7.3 takes several tens of milliseconds to occur (Fig. 1 A),
whereas a typical neuronal AP lasts less than a couple of
milliseconds (Fig. 5; Bean, 2007), highlights the apparent
disconnect between the kinetics of both processes. This
upholds the idea that, during the lifetime of an AP, the
number of activated KV7.2/KV7.3 channels likely remains
constant. In our view, this is consistent with the notion
that neuronal KV7 channels function as regulators of excitability by contributing the control of the resting potential
(Jentsch, 2000; Peters et al., 2005; Miceli et al., 2008;
Cooper, 2012). Thus, our observations indicate that the
voltage-dependent activation of KV7.2/KV7.3 channels
may constitute a mechanism that is physiologically relevant only at transmembrane voltages near the resting
potential. Therefore, the use of activation by depolarization to experimentally evaluate the effect of drugs or
mutations on these channels may not be suitable.
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